Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics (PRQR) Non-Current Assets (2016 - 2025)

ProQR Therapeutics' Non-Current Assets history spans 6 years, with the latest figure at $14.7 million for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 2.51% to $14.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $14.7 million, a 2.51% decrease, with the full-year FY2025 number at $14.7 million, down 2.51% from a year prior.
  • Non-Current Assets hit $14.7 million in Q4 2025 for ProQR Therapeutics, down from $15.1 million in the prior quarter.
  • Over the last five years, Non-Current Assets for PRQR hit a ceiling of $110.5 billion in Q1 2021 and a floor of $14.7 million in Q4 2025.
  • Historically, Non-Current Assets has averaged $7.9 billion across 5 years, with a median of $18.6 million in 2023.
  • Biggest five-year swings in Non-Current Assets: plummeted 99.98% in 2022 and later rose 6.24% in 2023.
  • Tracing PRQR's Non-Current Assets over 5 years: stood at $20.7 million in 2021, then dropped by 16.9% to $17.2 million in 2022, then grew by 5.68% to $18.2 million in 2023, then decreased by 17.05% to $15.1 million in 2024, then fell by 2.51% to $14.7 million in 2025.
  • Business Quant data shows Non-Current Assets for PRQR at $14.7 million in Q4 2025, $15.1 million in Q4 2024, and $18.2 million in Q4 2023.